Haemodynamic effect of endothelin, a novel potent vasoconstrictor in dogs

Clin Exp Pharmacol Physiol. 1990 May;17(5):351-60. doi: 10.1111/j.1440-1681.1990.tb01331.x.

Abstract

1. The effects of endothelin (40 and 400 pmol/kg, intravenous (i.v.), a novel vasoconstrictor, on haemodynamics were evaluated in normal dogs and dogs treated with hexamethonium. 2. The lower dose of endothelin caused no significant changes in mean blood pressure (MBP), heart rate (HR), cardiac output (CO), or total peripheral resistance (TPR) in normal dogs. In dogs treated with hexamethonium MBP decreased transiently associated with decrease in TPR. 3. In both dogs, the higher dose of endothelin caused MBP increase with CO increase in an early phase, and with TPR increase in a later phase. In normal dogs, the CO decreased 60 min after endothelin, but in dogs treated with hexamethonium the decrease in CO was not significant. 4. Electrocardiograms showed ST changes and arrhythmias. 5. Thus, endothelin has dual effects on both the vasculature and the heart, its effect depending on its dose and the time after its administration: initial vasodilation followed by prolonged vasoconstriction, and cardiostimulation followed by cardiosuppression. The cardiosuppression appears to be mediated in part by a neural mechanism.

MeSH terms

  • Animals
  • Cardiovascular System / drug effects
  • Dogs
  • Drug Administration Schedule
  • Electrocardiography / drug effects
  • Endothelins
  • Female
  • Ganglia / drug effects
  • Ganglionic Blockers / pharmacology
  • Hemodynamics / drug effects*
  • Hexamethonium
  • Hexamethonium Compounds / pharmacology
  • Injections, Intravenous
  • Male
  • Peptides / administration & dosage
  • Peptides / pharmacology*
  • Vasoconstriction / drug effects
  • Vasodilation / drug effects

Substances

  • Endothelins
  • Ganglionic Blockers
  • Hexamethonium Compounds
  • Peptides
  • Hexamethonium